Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Wilson's Disease.

Brewer1

  • 1Departments of Human Genetics and Internal Medicine, University of Michigan Medical School, 4708 Medical Science Bldg. II, Ann Arbor, MI 48109-0618, USA. brewergj@umich.edu

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Modified Regression Techniques to a Quantitative Assessment for the Motor Signs of Parkinson's Disease.

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society·2021
Same author

Novel Guidewire Design and Coating for Continuous Delivery of Adenosine During Interventional Procedures.

Journal of the American Heart Association·2021
Same author

Electron localization in a disordered insulating host

Physical review letters·2000
Same author

Low temperature limit of the vortex core radius and the kramer-pesch effect in NbSe2

Physical review letters·2000
Same author

28 days

BMJ (Clinical research ed.)·2000
Same author

Synthesis of "sugar-rods" with phytohemagglutinin cross-linking properties by using the palladium-catalyzed Sonogashira reaction

Chemistry (Weinheim an der Bergstrasse, Germany)·2000
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Effective anticopper therapy is crucial for Wilson's disease recovery. Treatment selection depends on disease stage and presentation, guiding choices between zinc, trientine, and tetrathiomolybdate for optimal patient outcomes.

Area of Science:

  • * Hepatology and Neurology
  • * Pharmacology and Therapeutics

Background:

  • * Wilson's disease is a genetic disorder characterized by excessive copper accumulation in organs.
  • * Untreated Wilson's disease can lead to severe liver damage, neurological dysfunction, and psychiatric disturbances.
  • * Anticopper therapy is essential for managing Wilson's disease and preventing irreversible organ damage.

Purpose of the Study:

  • * To outline a strategic approach for selecting appropriate anticopper therapy in Wilson's disease.
  • * To differentiate treatment protocols based on disease presentation and stage.

Main Methods:

  • * Clinical management strategies based on patient presentation (hepatic vs. neurologic/psychiatric).
  • * Therapeutic regimens tailored to disease phase (initial vs. maintenance).

Related Experiment Videos

  • * Utilized medications include zinc, trientine, and tetrathiomolybdate.

    • Main Results:

    • * Initial hepatic disease presentation managed with a combination of zinc and trientine.
    • * Initial neurologic/psychiatric disease presentation treated with tetrathiomolybdate.
    • * Maintenance phase therapy consistently involves zinc administration.

    Conclusions:

    • * Personalized anticopper therapy is critical for halting Wilson's disease progression and enabling patient recovery.
    • * Treatment selection must be individualized based on the specific clinical presentation and disease stage.
    • * The described therapeutic approach aims to optimize outcomes for patients with Wilson's disease.